Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease

Hematopoietic stem cell transplantation (HSCT) is being increasingly used as a curative approach for sickle cell disease (SCD). With the risk of graft-versus-host disease (GVHD), especially in the human leukocyte antigen−mismatched donors, intense immunosuppression is required leading to an increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Hannah, Mandava, Mamatha, Jensen-Wachspress, Mariah, Lang, Haili, Joy, Elisabeth, Tanna, Jay, McCann, Chase D., O’Brien, Samuel, Burnett, Sianna, Shibli, Abeer, Hoq, Fahmida, Bhatia, Monica, Hanley, Patrick J., Dávila Saldaña, Blachy, Mahadeo, Kris M., Bollard, Catherine M., Keller, Michael D., Abraham, Allistair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196792/
https://www.ncbi.nlm.nih.gov/pubmed/36516084
http://dx.doi.org/10.1182/bloodadvances.2022008219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196792/
https://www.ncbi.nlm.nih.gov/pubmed/36516084
http://dx.doi.org/10.1182/bloodadvances.2022008219

Ejemplares similares